indazoles has been researched along with tanespimycin in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aoki, Y; Fukami, TA; Hasegawa, K; Kim, SJ; Miura, T; Na, YJ; Ono, N; Shimma, N; Shindo, H; Shiratori, Y; Suda, A; Tsukuda, T; Yoon, DO | 1 |
| Amir, S; Mabjeesh, NJ | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Beraldi, E; Fazli, L; Gleave, ME; Kuruma, H; Lamoureux, F; Thomas, C; Yin, MJ; Zoubeidi, A | 1 |
| Adhikari, LJ; Ames, MM; Gilbert, JA; Halfdanarson, TR; Lloyd, RV; Muders, MH | 1 |
| Chrysikos, D; Dimopoulos, MA; Papadimitriou, CA; Psaltopoulou, T; Sergentanis, TN; Zagouri, F | 1 |
| Hoshino, D; Maldonado, AT; Tyson, DR; Weaver, AM; Wirtz, ED | 1 |
2 review(s) available for indazoles and tanespimycin
| Article | Year |
|---|---|
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
Hsp90 inhibitors in breast cancer: a systematic review.
Topics: Adenine; Antineoplastic Agents; Benzamides; Benzoquinones; Biomarkers, Tumor; Female; Glycine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Indazoles; Isoxazoles; Lactams, Macrocyclic; Pyridines; Resorcinols; Triazoles; Triple Negative Breast Neoplasms | 2013 |
5 other study(ies) available for indazoles and tanespimycin
| Article | Year |
|---|---|
Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
Topics: Adenosine Triphosphatases; Administration, Oral; Animals; Antineoplastic Agents; Benzopyrans; Computer Simulation; Dose-Response Relationship, Drug; Drug Design; Drug Discovery; Escherichia coli; HSP90 Heat-Shock Proteins; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Neoplasms; Reproducibility of Results; Structure-Activity Relationship; Surface Plasmon Resonance; Triazines; Xenograft Model Antitumor Assays | 2011 |
SEPT9_V1 protein expression is associated with human cancer cell resistance to microtubule-disrupting agents.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Benzoquinones; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lactams, Macrocyclic; Neoplasm Proteins; Paclitaxel; Protein Isoforms; Recombinant Fusion Proteins; RNA Interference; RNA, Messenger; RNA, Neoplasm; Septins; Transcription, Genetic; Tubulin Modulators | 2007 |
Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer.
Topics: Animals; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Clusterin; Drug Synergism; Glycine; Heat-Shock Response; HSP90 Heat-Shock Proteins; Humans; Indazoles; Lactams, Macrocyclic; Male; Mice; Mice, Nude; Prostatic Neoplasms; Thionucleotides; Xenograft Model Antitumor Assays | 2011 |
Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.
Topics: Axitinib; Benzoquinones; Biomarkers, Tumor; Carcinoid Tumor; Cell Line, Tumor; Cell Survival; Drug Therapy; ErbB Receptors; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Immunohistochemistry; In Situ Hybridization, Fluorescence; Indazoles; Lactams, Macrocyclic; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins p21(ras); Pyrazoles; ras Proteins; Receptor, ErbB-2; Receptor, IGF Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Transforming Growth Factor-beta Type I; Receptors, Somatostatin; Receptors, Transforming Growth Factor beta; Triazines; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Response of head and neck squamous cell carcinoma cells carrying PIK3CA mutations to selected targeted therapies.
Topics: Benzoquinones; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Class I Phosphatidylinositol 3-Kinases; Head and Neck Neoplasms; Humans; Imidazoles; Indazoles; Inhibitory Concentration 50; Lactams, Macrocyclic; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Pyridones; Pyrimidinones; Quinolines; Squamous Cell Carcinoma of Head and Neck; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2015 |